CN115413747A - Solid beverage and preparation method thereof - Google Patents
Solid beverage and preparation method thereof Download PDFInfo
- Publication number
- CN115413747A CN115413747A CN202211221115.4A CN202211221115A CN115413747A CN 115413747 A CN115413747 A CN 115413747A CN 202211221115 A CN202211221115 A CN 202211221115A CN 115413747 A CN115413747 A CN 115413747A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- solid beverage
- fatty acid
- butter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 45
- 239000007787 solid Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 72
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 31
- 235000014121 butter Nutrition 0.000 claims abstract description 30
- 235000013162 Cocos nucifera Nutrition 0.000 claims abstract description 28
- 244000060011 Cocos nucifera Species 0.000 claims abstract description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000002156 mixing Methods 0.000 claims abstract description 15
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 14
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 230000001954 sterilising effect Effects 0.000 claims abstract description 13
- 239000004386 Erythritol Substances 0.000 claims abstract description 12
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940009714 erythritol Drugs 0.000 claims abstract description 12
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 12
- 235000019414 erythritol Nutrition 0.000 claims abstract description 12
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 8
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 8
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 238000010298 pulverizing process Methods 0.000 claims abstract description 7
- 238000007873 sieving Methods 0.000 claims abstract description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 21
- 229930195729 fatty acid Natural products 0.000 claims description 21
- 239000000194 fatty acid Substances 0.000 claims description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- 102000011632 Caseins Human genes 0.000 claims description 19
- 108010076119 Caseins Proteins 0.000 claims description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- 239000008103 glucose Substances 0.000 claims description 15
- 239000003240 coconut oil Substances 0.000 claims description 14
- 235000019864 coconut oil Nutrition 0.000 claims description 14
- -1 glycerol fatty acid esters Chemical class 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 10
- 229930003268 Vitamin C Natural products 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 229940080237 sodium caseinate Drugs 0.000 claims description 10
- 235000019154 vitamin C Nutrition 0.000 claims description 10
- 239000011718 vitamin C Substances 0.000 claims description 10
- 239000005018 casein Substances 0.000 claims description 9
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 9
- 235000021240 caseins Nutrition 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 239000006188 syrup Substances 0.000 claims description 7
- 235000020357 syrup Nutrition 0.000 claims description 7
- 239000001508 potassium citrate Substances 0.000 claims description 6
- 229960002635 potassium citrate Drugs 0.000 claims description 6
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 6
- 235000011082 potassium citrates Nutrition 0.000 claims description 6
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 5
- GUOCOOQWZHQBJI-UHFFFAOYSA-N 4-oct-7-enoxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OCCCCCCC=C GUOCOOQWZHQBJI-UHFFFAOYSA-N 0.000 claims description 4
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 4
- 229940080313 sodium starch Drugs 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- VAYQNUBOZLPGDH-OLXJLDBKSA-N Monocerin Chemical group O1C(=O)C2=C(O)C(OC)=C(OC)C=C2[C@@H]2[C@H]1C[C@H](CCC)O2 VAYQNUBOZLPGDH-OLXJLDBKSA-N 0.000 claims description 2
- 229940105990 diglycerin Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 230000036541 health Effects 0.000 abstract description 6
- 230000001276 controlling effect Effects 0.000 abstract description 5
- 238000010923 batch production Methods 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 239000003925 fat Substances 0.000 description 17
- 235000019197 fats Nutrition 0.000 description 17
- 235000012000 cholesterol Nutrition 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 201000001421 hyperglycemia Diseases 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- 150000004667 medium chain fatty acids Chemical class 0.000 description 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000003613 bile acid Substances 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000001334 starch sodium octenyl succinate Substances 0.000 description 5
- 235000013826 starch sodium octenyl succinate Nutrition 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 150000004668 long chain fatty acids Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 230000000050 nutritive effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010018276 Gingival bleeding Diseases 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229940100228 acetyl coenzyme a Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000014786 phosphorus Nutrition 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000004141 reverse cholesterol transport Effects 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000132179 Eurotium medium Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- LUEWUZLMQUOBSB-UHFFFAOYSA-N UNPD55895 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(O)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O LUEWUZLMQUOBSB-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 208000011759 gum bleeding Diseases 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000021142 long-term diet Nutrition 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- UYQJCPNSAVWAFU-UHFFFAOYSA-N malto-tetraose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)O1 UYQJCPNSAVWAFU-UHFFFAOYSA-N 0.000 description 1
- LUEWUZLMQUOBSB-OUBHKODOSA-N maltotetraose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O[C@@H]3[C@@H](O[C@@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-OUBHKODOSA-N 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention provides a solid beverage and a preparation method thereof, and relates to the technical field of health care products. A solid beverage comprises the following components in parts by weight: 50-100 parts of medium-chain triglyceride powder, 1-10 parts of erythritol, 40-80 parts of coconut powder, 20-40 parts of butter powder, 1-10 parts of maltodextrin, 1-5 parts of silicon dioxide and 1-5 parts of edible essence. The preparation method comprises mixing medium chain triglyceride powder, coconut powder and butter powder, pulverizing the rest raw materials, sieving, adding, stirring, and sterilizing. The solid beverage has the effects of regulating three highs and controlling weight, can play a good role in health care, is simple and convenient to prepare, is suitable for batch production, and is convenient to popularize and apply.
Description
Technical Field
The invention relates to the technical field of health care products, and particularly relates to a solid beverage and a preparation method thereof.
Background
The three-high disease is a general term of hypertension, hyperlipidemia and hyperglycemia, and modern medical research proves that the three-high disease is a main factor for the formation and development of atherosclerosis, and the atherosclerosis is a main factor for causing blood cerebrovascular diseases. Hypertension is a clinical syndrome characterized by an increase in systemic arterial blood pressure (systolic pressure and/or diastolic pressure) and may be accompanied by functional or organic impairment of organs such as heart, brain, and kidney. Hyperlipidemia refers to the condition of high blood cholesterol or triglyceride or low high-density lipoprotein cholesterol, and is called as dyslipidemia in modern medicine. If the blood fat is too high, blood viscosity is easily caused, the blood is deposited on the blood vessel wall, atherosclerosis is gradually formed, the blood vessel is gradually blocked, the blood flow is slowed down, and the blood flow is interrupted when the blood flow is serious. Hyperglycemia, commonly known as diabetes, is a group of non-infectious chronic metabolic disorders characterized by hyperglycemia. It is characterized by a rapid rise in blood glucose levels after ingestion, resulting in blood glucose levels exceeding the body's glucose tolerance limits, often due to a deficiency in the body's insulin or a decrease in the sensitivity of its tissues to insulin.
At present, although various medicines and approaches exist for preventing and treating hyperglycemia, hyperlipidemia and hypertension, diet control becomes a method for most effectively helping to reduce hyperglycemia, hyperlipidemia and hypertension, but long-term diet control can affect appetite of people and experience feeling is poor. In the case of normal diet, the auxiliary three-high reduction through drinks becomes a more popular prevention and treatment method, so that a solid beverage for assisting three-high reduction is required to be provided.
Disclosure of Invention
The invention aims to provide a solid beverage which has the effects of regulating three highs and controlling weight and can play a good health-care role.
The invention also aims to provide a preparation method of the solid beverage, which is simple and convenient to prepare, suitable for batch production and convenient to popularize and apply.
The technical problem to be solved by the invention is realized by adopting the following technical scheme.
The invention provides a solid beverage which comprises the following raw materials in parts by weight: 50-100 parts of medium-chain triglyceride powder, 1-10 parts of erythritol, 40-80 parts of coconut powder, 20-40 parts of butter powder, 1-10 parts of maltodextrin, 1-5 parts of silicon dioxide and 1-5 parts of edible essence.
The invention provides a preparation method of a solid beverage, which comprises the following steps: mixing medium chain triglyceride powder, coconut powder and butter powder, pulverizing the rest materials, sieving, adding, stirring, and sterilizing.
The embodiment of the invention at least has the following beneficial effects:
in the invention, medium Chain Triglyceride (MCT) is less in molecular weight, is rapidly hydrolyzed into Medium Chain Fatty Acid (MCFA) and glycerol by lipase in intestinal tract after entering into organism, is absorbed by intestinal tract epithelial cells and then is combined with protein, is directly transported to liver through portal vein without passing through lymphocyte, directly enters mitochondria without action of carnitine transferase to carry out beta-oxidation, and finally is oxidized to generate CO 2 And H 2 O and release energy, which is not stored in the tissues of the human body such as fat, liver and muscle. Acetyl coenzyme A (CoA) produced by hydrolysate MCFA can enter the tricarboxylic acid cycle in mitochondria to be completely oxidized into carbon dioxide and water to release energy, or ketone bodies are generated to be used as energy substances by body tissues, so that the demand on glycogen and protein is reduced, and the effect of controlling body weight is achieved. The medium chain triglyceride has the characteristic of operation and absorption, can avoid intracellular lipid deposition caused by Long Chain Fatty Acid (LCFA) in tissues such as muscle, liver, fat and the like, is beneficial to improving insulin resistance of tissues and organs, and further improves the glycometabolism condition of an organism; meanwhile, reverse cholesterol transport can be promoted, cholesterol flows out through a transporter, a part of cholesterol is esterified under the catalysis of lecithin cholesterol acyl to be changed into High Density Lipoprotein (HDL), a liver surface receptor receives the cholesterol in the HDL to further synthesize bile acid, most of the bile acid enters into liver and intestine circulation, and a small part of the bile acid is discharged out of the body along with feces, so that cholesterol accumulation is reduced through a series of processes.
The coconut powder can balance the nutrition of the human body and improve the nutrient intake of the human body, thereby enhancing the immunity of the human body; the coconut powder contains antioxidant components, plays a role in neutralizing free radicals when contacting sunlight, and can promote metabolism of middle-aged and elderly people and blood circulation of human body; the trace elements contained in coconut powder has certain effect in preventing joint diseases and heart diseases of the middle aged and the elderly; the coconut powder contains various trace elements, so that black spots and freckles can be avoided, and the phenomenon of darkness of skin caused by poor blood circulation is changed, so that the skin is white; the rich vitamin E contained in the product can also renew old cell cutin and increase skin smoothness; the coconut powder contains abundant vitamins B1 and B2, vitamin C and carotene, and can promote blood circulation of capillary vessels, delay aging of a human body and help to remove free radicals accumulated by the human body; the coconut powder can also prevent constipation, kill parasites in human body, and make skin ruddy.
The butter powder can increase satiety, promote gastrointestinal peristalsis, strengthen gastrointestinal metabolism, reduce fat accumulation and achieve the purpose of controlling weight; can supplement a large amount of nutrient components for the organism, calm the nerves and help sleep, achieve the purpose of improving the immunity of the organism and further improve the disease resistance of the organism.
By matching the medium-chain triglyceride powder, the coconut powder and the butter powder, the solid beverage has rich nutritive value, good health-care effect, and is helpful for enhancing the immunity of the organism and preventing three highs, obesity, cardiovascular diseases, heart diseases and the like.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
It should be noted that the embodiments and features of the embodiments of the present invention may be combined with each other without conflict. The present invention will be described in detail below with reference to specific examples.
The solid beverage comprises the following raw materials in parts by weight: 50-100 parts of medium-chain triglyceride powder, 1-10 parts of erythritol, 40-80 parts of coconut powder, 20-40 parts of butter powder, 1-10 parts of maltodextrin, 1-5 parts of silicon dioxide and 1-5 parts of edible essence.
In this example, the medium chain triglyceride powder includes medium chain triglyceride, glucose syrup, sodium caseinate, dipotassium hydrogen phosphate and glycerol fatty acid ester.
Medium chain triglycerides, i.e. medium chain fats, naturally occur in food products such as palm kernel oil, coconut oil, etc. and in breast milk, are one of the sources of dietary fat, the main constituents being "caprylic, capric glycerides". Medium Chain Triglycerides (MCT) can be used for treating prostatic hyperplasia, eliminating gallstone, reducing cholesterol, and preventing and treating hyperlipidemia and cardiovascular diseases; can also supplement saturated fat required by human body, and make the fat burn to help to lose weight, and has obvious effects on reducing the weight of human body, the fat area of abdomen and the waist circumference.
The glucose syrup is produced by using starch as raw material under the action of enzyme or acid, and its main components are glucose, maltose, maltotriose, maltotetraose and tetrasaccharide, also called liquid glucose and glucose-wheat syrup. The liquid glucose has good anti-crystallization performance, oxidation resistance, good chemical stability and higher viscosity, can improve the consistency and palatability of products by utilizing the viscosity, has high osmotic pressure and higher sweetness, can be used as a sweetening agent, and has the advantages of long shelf life and difficult change of product taste. The liquid glucose has good reducibility and low chemical stability under neutral and alkaline conditions, is easily decomposed to generate a colored substance by heating, is also easily coked with a protein nitrogen-containing substance to generate brown yellow caramel, and has a special flavor.
The sodium caseinate, which is generally referred to as sodium caseinate, is also called sodium caseinate, sodium caseinate or casein, is a sodium salt of casein which is a main protein in milk, and is a safe and harmless thickener and emulsifier. The sodium caseinate is a protein supplement, and casein can promote the growth and repair of muscle tissues, is rich in various amino acids and can supplement nutrition for organisms.
Erythritol is a bulk sweetener, is a four-carbon sugar alcohol, and has a molecular formula of C 4 H 10 O 4 Has a refreshing sweet taste, is stable at high temperatures, is stable over a wide pH range, and has a mild cooling sensation when dissolved in the mouth. The erythritol can increase sweetness, thickness and lubrication of the beverage, reduce bitterness, mask other odors and improve beverage flavor. Erythritol is used for solid beverages and can refresh, particularly because erythritol absorbs a large amount of heat when dissolved. Erythritol can also obviously improve the bad odor of plant extracts, collagen, peptides and other substances, thereby improving the mouthfeel.
Maltodextrin is a tasteless, nutritive polysaccharide intermediate between starch and starch sugar, is inexpensive, tastes smooth, and is used as a bulking agent and thickener.
In this example, coconut flour includes coconut oil, sodium starch octenyl succinate, vitamin C and glycerol fatty acid ester.
The most predominant saturated fatty acid in coconut oil is lauric acid, 47% to 54%, and further comprises 18% of myristic acid, 10% of palmitic acid, 2% of stearic acid, etc. Coconut oil has very strong antibacterial ability, so it has strong phagocytosis effect to various bacterial viruses, can promote phagocyte to destroy it, and can also enhance the body's immunity. Besides, the coconut oil has very strong oxidation resistance, so that the coconut oil can repair and activate the vitality of cells and remove free radicals harmful to body health, thereby achieving the effect of building the body. Coconut oil can enhance the permeability of blood vessels, so that the coconut oil has stronger toughness, can clear redundant fat and garbage in blood, and can prevent arteriosclerosis, thereby having good effect on preventing and treating cardiovascular and cerebrovascular diseases. In addition, the high stability and non-oxidative nature of the pure fresh coconut oil prevents it from decaying in the body and accumulating toxins with other foods, which increases the physical burden. The medium-chain fatty acid of the pure fresh coconut oil has strong exclusivity on toxin, and various fatty acids with strong antibacterial function can effectively kill harmful viruses in the body and gradually discharge accumulated toxin out of the body, thereby having better health care effect.
Starch sodium octenyl succinate is an emulsifying thickener with high safety, when the starch sodium octenyl succinate acts on an oil/water emulsion, hydrophilic carboxylic acid groups of the starch sodium octenyl succinate extend into water, lipophilic octenyl long chains extend into oil, and a tough and unbreakable film is formed by long polysaccharide chains on an oil-water interface, so that dispersed phase particles are difficult to aggregate and separate, and the starch sodium octenyl succinate has very good emulsifying and thickening properties.
Vitamin C is a polyhydroxy compound having the formula C 6 H 8 O 6 Vitamin C is necessary for antibody and collagen formation, tissue repair (including certain redox actions), metabolism of phenylalanine, tyrosine and folic acid, utilization of iron and carbohydrate, synthesis of fat and protein, maintenance of immune function, hydroxylation of 5-hydroxytryptamine, blood vessel integrity maintenance, non-heme iron absorption promotion and the like, and simultaneously the vitamin C also has the effects of oxidation resistance, free radical resistance and tyrosinase inhibition, so that the effects of whitening and spot lightening are achieved. The vitamin C promotes the biosynthesis of ossein, is beneficial to the faster healing of tissue wounds, promotes the metabolism of tyrosine and tryptophan in amino acid, and prolongs the life of organisms; improving the utilization of iron, calcium and folic acid; improving the metabolism of fats and lipids, especially cholesterol, and preventing cardiovascular diseases; promoting growth of teeth and bones, preventing gum bleeding, and preventing arthralgia, lumbago, and skelalgia; enhancing the anti-stress capability and immunity of the organism to the external environment; firm connective tissue; promoting collagen synthesis, and preventing gingival bleeding.
In this example, the butter powder includes anhydrous butter, resistant dextrin, casein, potassium citrate, glycerin fatty acid ester, and silicon dioxide.
The anhydrous butter has fine crystals, good whipping property and excellent fragrance retention, is high-quality pure butter fat, does not contain any additive pigment, has the effects of improving the mouthfeel and the fat solubility, and contains fatty triglyceride acid to blend the grease. The components of the health-care food are mainly fat and water, and simultaneously contain nutrients such as protein, cholesterol, riboflavin, calcium, phosphorus and the like and minerals, so that the health-care food can provide special aroma, increase flavor and nutrition and supplement heat energy. Butter is rich in fat, maintains body temperature and protects internal organs, provides essential fatty acids, promotes absorption of these fat-soluble vitamins, and increases satiety; copper is rich in copper, is an indispensable micronutrient for human health, and has important influence on the development and functions of blood, central nervous system and immune system, hair, skin and skeletal tissues, and internal organs such as brain, liver, heart and the like; is rich in amino acids, proteins, various vitamins such as vitamin A and the like and mineral substances, and can supplement a large amount of nutrition for the development of the body and the development of bones; can also be used for improving anemia.
The resistant dextrin is low-calorie glucan, belongs to low-molecular water-soluble dietary fiber, and is added into the solid beverage to enable the biological functions of the resistant dextrin and intestinal beneficial bacteria such as lactic acid bacteria, bifidobacteria and the like to be more fully exerted, so that a great synergistic effect is generated.
Casein is a binding protein containing calcium phosphate, and can promote bone health, prevent osteoporosis and diabetes, regulate blood pressure, promote muscle growth, assist sleep, reduce anxiety, inhibit nerve hyperexcitability, and promote sleep. Can be used as nutrition enhancer, thickening and emulsifying stabilizer, or binder, filler, and carrier.
The potassium citrate is used as an acidic flavoring agent, so that the beverage presents a sour and sweet taste, the sensory properties of the beverage are improved, the appetite is enhanced, and the digestion and absorption of calcium and phosphorus substances in vivo are promoted.
The silicon dioxide can prevent the components from aggregating and agglomerating, and improve the preparation speed of the solid beverage. And the silicon dioxide has large specific surface area, can play a role of a spacing agent among particles of the powder substance, promotes the free flow of the powder substance, has extremely high moisture absorption performance, and can enhance the anti-caking effect and the adsorption effect.
In this example, glycerin fatty acid ester is a mono-or diglycerin fatty acid ester, and has an effect of emulsifying, dispersing and thickening, and can improve the stability of the beverage and prevent the beverage from deteriorating.
A method for preparing a solid beverage, comprising the steps of: mixing medium chain triglyceride powder, coconut powder and butter powder, pulverizing the rest raw materials, sieving with 100-150 mesh sieve, stirring at 80-120rpm for 10-30min, sterilizing with instantaneous sterilizing equipment for 3-10s, and packaging.
On the premise of ensuring normal diet, the solid beverage disclosed by the invention can be used for assisting in reducing the three highs through the beverage, so that the use feeling of people is better, the popularity is higher, and the solid beverage is more convenient to popularize and apply. When packaging, bags with 20g of each bag are selected. The shape of the bottle can also be selected according to specific conditions when special requirements are met.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
A method for preparing a solid beverage, comprising the steps of:
raw materials: 50g of medium chain triglyceride powder, 1g of erythritol, 40g of coconut powder, 20g of butter powder, 1g of maltodextrin, 1g of silicon dioxide and 1g of edible essence;
medium chain triglyceride powder: mixing 80g of medium chain triglyceride, 5g of glucose syrup, 1g of sodium caseinate, 1g of dipotassium hydrogen phosphate and 1g of mono-and diglycerol fatty acid esters, homogenizing and drying;
coconut powder: mixing 60g of coconut oil, 1g of starch sodium octenylsuccinate, 1g of vitamin C and 1g of mono-diglycerol fatty acid ester, homogenizing and drying;
butter powder: mixing 40g anhydrous butter, 1g resistant dextrin, 1g casein, 1g potassium citrate, 1g mono-diglycerol fatty acid ester and 1g silicon dioxide, homogenizing and drying;
mixing medium chain triglyceride powder, coconut powder and butter powder, pulverizing the rest materials, sieving with 100 mesh sieve, stirring at 80rpm for 10min, sterilizing with instantaneous sterilizing equipment for 3s, and packaging.
Example 2
A method for preparing a solid beverage, comprising the steps of:
raw materials: 80g of medium chain triglyceride powder, 2g of erythritol, 50g of coconut powder, 30g of butter powder, 5g of maltodextrin, 2g of silicon dioxide and 2g of edible essence;
medium chain triglyceride powder: mixing 90g of medium chain triglyceride, 10g of glucose syrup, 3g of sodium caseinate, 2g of dipotassium hydrogen phosphate and 5g of mono-diglycerol fatty acid ester and drying;
coconut powder: 70g of coconut oil, 5g of sodium starch octenylsuccinate, 2g of vitamin C and 3g of mono-diglycerol fatty acid ester, and mixing, homogenizing and drying the raw materials;
and (3) butter powder: mixing 50g of anhydrous butter, 2g of resistant dextrin, 5g of casein, 2g of potassium citrate, 5g of mono-diglycerol fatty acid ester and 2g of silicon dioxide, homogenizing and drying;
mixing medium chain triglyceride powder, coconut powder and butter powder, pulverizing the rest materials, sieving with 130 mesh sieve, stirring at 100rpm for 20min, sterilizing with instant sterilizing equipment for 6s, and packaging.
Example 3
A method for preparing a solid beverage comprises the following steps:
raw materials: 100g of medium chain triglyceride powder, 10g of erythritol, 80g of coconut powder, 40g of butter powder, 10g of maltodextrin, 5g of silicon dioxide and 5g of edible essence;
medium chain triglyceride powder: 100g of medium chain triglyceride, 15g of glucose syrup, 8g of sodium caseinate, 5g of dipotassium hydrogen phosphate and 10g of mono-diglycerol fatty acid ester and diglycerol fatty acid ester are mixed, homogenized and dried;
coconut powder: 80g of coconut oil, 10g of sodium starch octenylsuccinate, 10g of vitamin C and 10g of mono-diglycerol fatty acid ester, and mixing, homogenizing and drying the raw materials;
and (3) butter powder: 60g of anhydrous butter, 5g of resistant dextrin, 10g of casein, 5g of potassium citrate, 10g of mono-diglycerol fatty acid ester and 5g of silicon dioxide, and mixing, homogenizing and drying the raw materials;
mixing medium chain triglyceride powder, coconut powder and butter powder, pulverizing the rest materials, sieving with 150 mesh sieve, stirring at 120rpm for 30min, sterilizing with instantaneous sterilization equipment for 10s, and packaging.
Comparative example 1
This comparative example differs from example 1 in that no medium chain triglyceride powder was included in the feed.
Comparative example 2
This comparative example differs from example 1 in that no coconut flour was included in the starting material.
Test results
5 subjects with hypertension symptoms are selected to be sequentially 1-5 groups, the solid beverages of examples 1-3 and comparative examples 1-2 are respectively used, other antihypertensive drugs are not taken in the using process, the diet and the living habits have no significant difference, the dose is 20 g/time, the administration is 2 times per day, the administration is continuously carried out for 3 months, and the using conditions are as follows:
TABLE 1 blood pressure changes
As can be seen from Table 1, compared with comparative examples 1-2, the blood pressure of the testees in examples 1-3 is reduced significantly and is lower than the hypertension standard, which shows that the solid beverage prepared in the example of the invention has the function of reducing blood pressure and can regulate the body hypertension.
The experimental design of 5 cases of testers with hyperlipidemia symptoms is as above, and the using results are as follows:
TABLE 2 blood lipid changes
As can be seen from Table 2, compared with comparative examples 1-2, the total cholesterol and triacylglycerols in plasma of the testers in examples 1-3 are reduced obviously and are lower than the standard of hyperlipemia, which shows that the solid beverage prepared by the embodiment of the invention has the function of reducing blood fat and can regulate the hyperlipemia of organisms.
Alternatively, in 5 cases of the subjects with hyperglycemia, the test was designed as described above, and the following blood glucose values were fasting blood glucose values, respectively, and the results after use were as follows:
TABLE 3 blood glucose Change
Group of | Initial blood glucose content/(mmol/L) | Blood glucose content after 3 months/(mmol/L) |
Example 1 | 10.8 | 5.5 |
Example 2 | 10.5 | 4.8 |
Example 3 | 9.5 | 5.9 |
Comparative example 1 | 9.8 | 6.7 |
Comparative example 2 | 10.6 | 6.3 |
As can be seen from Table 3, compared with comparative examples 1-2, the blood sugar of the testees of examples 1-3 is reduced significantly and is lower than the hyperglycemia standard, which shows that the solid beverage prepared by the invention has the function of reducing blood sugar and can regulate the hyperglycemia of the body.
In summary, in the solid beverage according to the embodiment of the present invention, medium-chain triglycerides (MCT) having a low molecular weight are rapidly hydrolyzed into medium-chain fatty acids (MCFA) and glycerol in the intestinal tract by lipase after entering the body, are absorbed by intestinal epithelial cells, are bound to proteins, and are directly transported to the liver through the portal vein without passing through lymphocytes, and directly enter mitochondria without the action of carnitine transferase to perform β -oxidation, and are finally oxidized to generate CO 2 And H 2 O and release energy, which is not stored in the tissues of the human body such as fat, liver and muscle. Acetyl coenzyme A (CoA) produced by hydrolysate MCFA can enter the tricarboxylic acid cycle in mitochondria to be completely oxidized into carbon dioxide and water to release energy, or ketone bodies are generated to be used as energy substances by body tissues, so that the demand on glycogen and protein is reduced, and the effect of controlling body weight is achieved. The medium chain triglyceride has the characteristic of operation and absorption, can avoid intracellular lipid deposition caused by Long Chain Fatty Acid (LCFA) in tissues such as muscle, liver, fat and the like, is beneficial to improving insulin resistance of tissues and organs, and further improves the glycometabolism condition of an organism; meanwhile, reverse cholesterol transport can be promoted, cholesterol flows out through a transporter, a part of cholesterol is esterified under the catalysis of lecithin cholesterol acyl to become High Density Lipoprotein (HDL), a liver surface receptor receives the cholesterol in the HDL to further synthesize bile acid, most of the bile acid enters liver and intestine circulation, and the small part of the bile acid is discharged out of the body along with feces, so that cholesterol accumulation is reduced through a series of processes. By matching the medium-chain triglyceride powder, the coconut powder and the butter powder, the solid beverage has rich nutritive value, good health-care effect, and is helpful for enhancing the immunity of the organism and preventing three highs, obesity, cardiovascular diseases, heart diseases and the like.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (9)
1. The solid beverage is characterized by comprising the following raw materials in parts by weight: 50-100 parts of medium-chain triglyceride powder, 1-10 parts of erythritol, 40-80 parts of coconut powder, 20-40 parts of butter powder, 1-10 parts of maltodextrin, 1-5 parts of silicon dioxide and 1-5 parts of edible essence.
2. The solid beverage according to claim 1, wherein the medium chain triglyceride powder comprises medium chain triglycerides, glucose syrup, sodium caseinate, dipotassium hydrogen phosphate and glycerol fatty acid esters.
3. The solid beverage according to claim 2, wherein the coconut powder comprises coconut oil, sodium starch octenyl succinate, vitamin C and glycerin fatty acid ester.
4. The solid beverage according to claim 3, wherein the butter powder comprises anhydrous butter, resistant dextrin, casein, potassium citrate, glycerin fatty acid ester and silicon dioxide.
5. The solid beverage according to any one of claims 2 to 4, wherein the glycerin fatty acid ester is a mono-or diglycerin fatty acid ester.
6. A method of preparing a solid beverage as claimed in any one of claims 1 to 5, comprising the steps of: mixing medium chain triglyceride powder, coconut powder and butter powder, pulverizing the rest raw materials, sieving, adding, stirring, and sterilizing.
7. The method for producing a solid beverage according to claim 6, wherein the number of the mesh openings is 100 to 150 mesh when the solid beverage is ground and sieved.
8. The method for preparing a solid beverage according to claim 6, wherein the stirring is carried out at 80 to 120rpm for 10 to 30min.
9. A method for preparing a solid beverage according to claim 6, wherein the sterilization is performed for 3 to 10 seconds by using an instantaneous sterilization apparatus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211221115.4A CN115413747A (en) | 2022-10-08 | 2022-10-08 | Solid beverage and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211221115.4A CN115413747A (en) | 2022-10-08 | 2022-10-08 | Solid beverage and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115413747A true CN115413747A (en) | 2022-12-02 |
Family
ID=84205338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211221115.4A Pending CN115413747A (en) | 2022-10-08 | 2022-10-08 | Solid beverage and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115413747A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108175016A (en) * | 2018-01-03 | 2018-06-19 | 杭州衡美食品科技有限公司 | A kind of raw ketone solid beverage and preparation method thereof |
CN108741029A (en) * | 2018-05-28 | 2018-11-06 | 广州正广生物科技有限公司 | High fat diet nutrient powder and preparation method thereof |
CN112369606A (en) * | 2020-11-09 | 2021-02-19 | 拜尔普兰(厦门)生物药业有限公司 | Low-carbon ketogenic food and preparation method thereof |
CN114208989A (en) * | 2021-12-27 | 2022-03-22 | 华润圣海健康科技有限公司 | Ketogenic meal replacement nutrition powder solid beverage and preparation method thereof |
-
2022
- 2022-10-08 CN CN202211221115.4A patent/CN115413747A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108175016A (en) * | 2018-01-03 | 2018-06-19 | 杭州衡美食品科技有限公司 | A kind of raw ketone solid beverage and preparation method thereof |
CN108741029A (en) * | 2018-05-28 | 2018-11-06 | 广州正广生物科技有限公司 | High fat diet nutrient powder and preparation method thereof |
CN112369606A (en) * | 2020-11-09 | 2021-02-19 | 拜尔普兰(厦门)生物药业有限公司 | Low-carbon ketogenic food and preparation method thereof |
CN114208989A (en) * | 2021-12-27 | 2022-03-22 | 华润圣海健康科技有限公司 | Ketogenic meal replacement nutrition powder solid beverage and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60126104T2 (en) | NUTRITIONAL COMPOSITION AND METHOD FOR IMPROVING THE DISPOSAL OF PROTEINS | |
CN101925307A (en) | High energy liquid enteral nutritional composition | |
JPH09191852A (en) | Healthy food | |
CN108685100A (en) | A kind of compound small peptide powder formula and preparation method thereof | |
CN112369606A (en) | Low-carbon ketogenic food and preparation method thereof | |
CN101049150A (en) | Edible nourishment health care potassium salt with extensive use | |
CN106690331A (en) | Kelp dietary fiber granules and preparation method thereof | |
CN106723087A (en) | A kind of tablet containing kelp dietary fiber and preparation method thereof | |
TW201635920A (en) | Muscle synthesis promoter | |
JP2004065018A (en) | Health food product | |
JP3720496B2 (en) | Novel pectin and emulsion containing the same | |
CN105341300A (en) | Health-care candies suitable for children to eat | |
CN104757689A (en) | Solid beverage with pine pollen, taurine and vitamins, and preparation method of the solid beverage | |
WO2023213325A1 (en) | High-energy beverage prepared by combining and synergistically refining ultra-high-purity octacosanol-flavonoid compound and deuterated water, and preparation method therefor | |
CN104720069A (en) | Chinese yam, Chinese date and vitamin fortified solid drink and preparation method thereof | |
CN110584120A (en) | Bone health composition | |
US20060210606A1 (en) | Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood | |
KR20170109380A (en) | manufacturing method of sweet jelly containing mealworm and sweet jelly containing mealworm made by the same | |
CN115413747A (en) | Solid beverage and preparation method thereof | |
JP2001269135A (en) | Nutritional composition capable of promoting body protein accumulation efficiency | |
CN112690386A (en) | A dietetic composition with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular and immunity | |
JP2009034017A (en) | Diet food | |
KR20210041387A (en) | A natural tea removing the effect of hangover contained the extract material in arrowroot blossoms and Plantago ovata | |
JP2007117094A (en) | Health food containing milk fermented product and herb | |
JP2006075176A (en) | Soybean milk kefir and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |